Pelthos Therapeutics Inc., formed in mid-2025 via merger, reported operational updates for Q1 2026 emphasizing early-stage commercialization of its dermatology product portfolio anchored by ZELSUVMI. The company maintains a strong IP moat around its proprietary NITRICIL platform and FDA-approved offerings while navigating typical biopharma commercialization challenges, including persistent operating losses. Pelthos holds $32 million in cash with a solid current ratio, providing runway to advance launches of newly acquired products XEPI and XEGLYZE. The competitive dermatology market, payer dynamics, and need for sustainable revenue remain key growth constraints to monitor.